SBH CRC MMR deficiency
2026-04-94
## Warning: NAs introduced by coercionDemographics
By First IO
| Nivolumab + Ipilimumab (N=10) |
Pembrolizumab (N=21) |
Total (N=31) |
|
|---|---|---|---|
| Gender | |||
| Female | 4 (40.0%) | 9 (42.9%) | 13 (41.9%) |
| Male | 6 (60.0%) | 12 (57.1%) | 18 (58.1%) |
| Age_dx | |||
| Mean (SD) | 58.8 (14.6) | 64.0 (14.7) | 62.3 (14.7) |
| Median [Min, Max] | 57.0 [42.0, 88.0] | 67.0 [38.0, 82.0] | 65.0 [38.0, 88.0] |
| YearGroup | |||
| <51yo | 4 (40.0%) | 4 (19.0%) | 8 (25.8%) |
| >50yo | 6 (60.0%) | 17 (81.0%) | 23 (74.2%) |
| Ethnicity1 | |||
| Asian | 3 (30.0%) | 4 (19.0%) | 7 (22.6%) |
| Black | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| Other | 1 (10.0%) | 0 (0%) | 1 (3.2%) |
| White | 6 (60.0%) | 16 (76.2%) | 22 (71.0%) |
| Ethnicity2 | |||
| Non-White | 4 (40.0%) | 5 (23.8%) | 9 (29.0%) |
| White | 6 (60.0%) | 16 (76.2%) | 22 (71.0%) |
| Site | |||
| Right | 8 (80.0%) | 14 (66.7%) | 22 (71.0%) |
| Left | 2 (20.0%) | 7 (33.3%) | 9 (29.0%) |
| LynchSyndrome | |||
| No | 7 (70.0%) | 14 (66.7%) | 21 (67.7%) |
| Si | 0 (0%) | 4 (19.0%) | 4 (12.9%) |
| Missing | 3 (30.0%) | 3 (14.3%) | 6 (19.4%) |
| T_dx | |||
| 2 | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| 3 | 1 (10.0%) | 9 (42.9%) | 10 (32.3%) |
| 4 | 9 (90.0%) | 11 (52.4%) | 20 (64.5%) |
| N_dx | |||
| 0 | 1 (10.0%) | 3 (14.3%) | 4 (12.9%) |
| 1 | 6 (60.0%) | 12 (57.1%) | 18 (58.1%) |
| 2 | 3 (30.0%) | 6 (28.6%) | 9 (29.0%) |
| M_dx | |||
| 0 | 6 (60.0%) | 8 (38.1%) | 14 (45.2%) |
| 1 | 4 (40.0%) | 11 (52.4%) | 15 (48.4%) |
| x | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| T.prior.ICI | |||
| 4a | 5 (50.0%) | 1 (4.8%) | 6 (19.4%) |
| 4b | 2 (20.0%) | 3 (14.3%) | 5 (16.1%) |
| x | 3 (30.0%) | 7 (33.3%) | 10 (32.3%) |
| 3 | 0 (0%) | 3 (14.3%) | 3 (9.7%) |
| 3a | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| 3b | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| 4 | 0 (0%) | 5 (23.8%) | 5 (16.1%) |
| N.prior.ICI | |||
| 0 | 1 (10.0%) | 2 (9.5%) | 3 (9.7%) |
| 1 | 3 (30.0%) | 6 (28.6%) | 9 (29.0%) |
| 2 | 2 (20.0%) | 5 (23.8%) | 7 (22.6%) |
| 2b | 1 (10.0%) | 0 (0%) | 1 (3.2%) |
| x | 3 (30.0%) | 7 (33.3%) | 10 (32.3%) |
| 1b | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| M.prior.ICI | |||
| 0 | 4 (40.0%) | 5 (23.8%) | 9 (29.0%) |
| 1 | 6 (60.0%) | 12 (57.1%) | 18 (58.1%) |
| 1a | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| 1b | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| 1c | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| Lymph.nodes | |||
| No | 10 (100%) | 19 (90.5%) | 29 (93.5%) |
| Si | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| Lung.mets | |||
| No | 10 (100%) | 18 (85.7%) | 28 (90.3%) |
| Si | 0 (0%) | 3 (14.3%) | 3 (9.7%) |
| Liver.mets | |||
| No | 9 (90.0%) | 16 (76.2%) | 25 (80.6%) |
| Si | 1 (10.0%) | 5 (23.8%) | 6 (19.4%) |
| Bone.mets | |||
| No | 10 (100%) | 21 (100%) | 31 (100%) |
| Si | 0 (0%) | 0 (0%) | 0 (0%) |
| Differentiation | |||
| Moderate | 5 (50.0%) | 15 (71.4%) | 20 (64.5%) |
| Poor | 5 (50.0%) | 6 (28.6%) | 11 (35.5%) |
| Loss.MLH1 | |||
| No | 1 (10.0%) | 7 (33.3%) | 8 (25.8%) |
| Si | 9 (90.0%) | 14 (66.7%) | 23 (74.2%) |
| Loss.MSH2 | |||
| No | 7 (70.0%) | 17 (81.0%) | 24 (77.4%) |
| Si | 3 (30.0%) | 4 (19.0%) | 7 (22.6%) |
| Loss.MSH6 | |||
| No | 7 (70.0%) | 17 (81.0%) | 24 (77.4%) |
| Si | 3 (30.0%) | 4 (19.0%) | 7 (22.6%) |
| Loss.PMS2 | |||
| No | 1 (10.0%) | 5 (23.8%) | 6 (19.4%) |
| Si | 9 (90.0%) | 16 (76.2%) | 25 (80.6%) |
| MLH1.Promoter | |||
| No | 2 (20.0%) | 2 (9.5%) | 4 (12.9%) |
| Si | 3 (30.0%) | 3 (14.3%) | 6 (19.4%) |
| Missing | 5 (50.0%) | 16 (76.2%) | 21 (67.7%) |
| BRAFmut | |||
| No | 6 (60.0%) | 11 (52.4%) | 17 (54.8%) |
| Si | 4 (40.0%) | 9 (42.9%) | 13 (41.9%) |
| Missing | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| BRAF.mut..specify. | |||
| V600E | 4 (40.0%) | 9 (42.9%) | 13 (41.9%) |
| Missing | 6 (60.0%) | 12 (57.1%) | 18 (58.1%) |
| KRASmut | |||
| No | 6 (60.0%) | 15 (71.4%) | 21 (67.7%) |
| Si | 4 (40.0%) | 5 (23.8%) | 9 (29.0%) |
| Missing | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| KRAS.mut..specify. | |||
| A146W | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| G12D | 2 (20.0%) | 0 (0%) | 2 (6.5%) |
| G12D, A146W | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| G12D, G12R | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| G12W | 1 (10.0%) | 0 (0%) | 1 (3.2%) |
| G13D | 1 (10.0%) | 1 (4.8%) | 2 (6.5%) |
| Missing | 6 (60.0%) | 16 (76.2%) | 22 (71.0%) |
| PIK3CAmut | |||
| No | 7 (70.0%) | 11 (52.4%) | 18 (58.1%) |
| Si | 3 (30.0%) | 9 (42.9%) | 12 (38.7%) |
| Missing | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| TP53mut | |||
| No | 7 (70.0%) | 16 (76.2%) | 23 (74.2%) |
| Si | 3 (30.0%) | 4 (19.0%) | 7 (22.6%) |
| Missing | 0 (0%) | 1 (4.8%) | 1 (3.2%) |
| CEA.dx.positive | |||
| No | 4 (40.0%) | 7 (33.3%) | 11 (35.5%) |
| Si | 5 (50.0%) | 9 (42.9%) | 14 (45.2%) |
| Missing | 1 (10.0%) | 5 (23.8%) | 6 (19.4%) |
| CA19.9.dx.positive | |||
| No | 4 (40.0%) | 3 (14.3%) | 7 (22.6%) |
| Si | 2 (20.0%) | 2 (9.5%) | 4 (12.9%) |
| Missing | 4 (40.0%) | 16 (76.2%) | 20 (64.5%) |
| Setting.Prior.IO | |||
| Locally Advanced | 4 (40.0%) | 5 (23.8%) | 9 (29.0%) |
| Metastatic | 6 (60.0%) | 16 (76.2%) | 22 (71.0%) |
| Surgery | |||
| No | 2 (20.0%) | 9 (42.9%) | 11 (35.5%) |
| Si | 8 (80.0%) | 12 (57.1%) | 20 (64.5%) |
| PO.Therapy | |||
| No | 10 (100%) | 15 (71.4%) | 25 (80.6%) |
| NeoA | 0 (0%) | 4 (19.0%) | 4 (12.9%) |
| Adj | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| Type.Surgery | |||
| None | 4 (40.0%) | 9 (42.9%) | 13 (41.9%) |
| Elective | 3 (30.0%) | 9 (42.9%) | 12 (38.7%) |
| Emergency | 2 (20.0%) | 2 (9.5%) | 4 (12.9%) |
| Symptom control | 1 (10.0%) | 1 (4.8%) | 2 (6.5%) |
| IO.Prior.Surgery | |||
| No | 8 (80.0%) | 17 (81.0%) | 25 (80.6%) |
| Si | 2 (20.0%) | 4 (19.0%) | 6 (19.4%) |
| number.ipilimumab | |||
| 1 | 4 (40.0%) | 0 (0%) | 4 (12.9%) |
| 4 | 6 (60.0%) | 0 (0%) | 6 (19.4%) |
| Missing | 0 (0%) | 21 (100%) | 21 (67.7%) |
| X1L.NLR.at.week.0 | |||
| Mean (SD) | 3.27 (1.09) | 4.41 (3.45) | 4.04 (2.93) |
| Median [Min, Max] | 2.93 [1.50, 5.20] | 3.55 [0.890, 15.7] | 3.33 [0.890, 15.7] |
| NLR.week0 | |||
| ≥3 | 4 (40.0%) | 13 (61.9%) | 17 (54.8%) |
| <3 | 6 (60.0%) | 8 (38.1%) | 14 (45.2%) |
| X1L.NLR.at.week.12 | |||
| Mean (SD) | 3.05 (2.44) | 2.88 (3.06) | 2.94 (2.82) |
| Median [Min, Max] | 2.25 [1.17, 9.40] | 2.19 [1.08, 15.1] | 2.19 [1.08, 15.1] |
| Missing | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| NLR.week12 | |||
| ≥3 | 4 (40.0%) | 4 (19.0%) | 8 (25.8%) |
| <3 | 6 (60.0%) | 15 (71.4%) | 21 (67.7%) |
| Missing | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| CEA_week0 | |||
| Mean (SD) | 249 (766) | 24.1 (41.9) | 102 (449) |
| Median [Min, Max] | 6.50 [2.60, 2430] | 9.40 [1.10, 176] | 7.00 [1.10, 2430] |
| Missing | 0 (0%) | 2 (9.5%) | 2 (6.5%) |
| CEA_week12 | |||
| Mean (SD) | 11.0 (17.1) | 57.6 (191) | 38.9 (148) |
| Median [Min, Max] | 2.55 [1.00, 50.9] | 3.50 [1.20, 747] | 3.20 [1.00, 747] |
| Missing | 0 (0%) | 6 (28.6%) | 6 (19.4%) |
| Response | |||
| CR | 2 (20.0%) | 1 (4.8%) | 3 (9.7%) |
| PR | 5 (50.0%) | 7 (33.3%) | 12 (38.7%) |
| SD | 1 (10.0%) | 7 (33.3%) | 8 (25.8%) |
| PD | 1 (10.0%) | 4 (19.0%) | 5 (16.1%) |
| Missing | 1 (10.0%) | 2 (9.5%) | 3 (9.7%) |
| PFSm | |||
| Mean (SD) | 6.22 (2.52) | 15.0 (13.9) | 12.1 (12.1) |
| Median [Min, Max] | 6.28 [3.55, 10.6] | 10.9 [-2.76, 53.7] | 8.61 [-2.76, 53.7] |
| OSm | |||
| Mean (SD) | 6.46 (2.35) | 17.8 (13.6) | 14.2 (12.4) |
| Median [Min, Max] | 6.62 [3.55, 10.6] | 13.9 [0.821, 53.7] | 10.8 [0.821, 53.7] |
| x1L.Tox.G3.4 | |||
| No | 6 (60.0%) | 10 (47.6%) | 16 (51.6%) |
| Si | 4 (40.0%) | 8 (38.1%) | 12 (38.7%) |
| Missing | 0 (0%) | 3 (14.3%) | 3 (9.7%) |
| x1L.IO.Tox.PDN | |||
| No | 8 (80.0%) | 19 (90.5%) | 27 (87.1%) |
| Si | 2 (20.0%) | 2 (9.5%) | 4 (12.9%) |
Graphics
By Setting
| Locally Advanced (N=9) |
Metastatic (N=22) |
Total (N=31) |
|
|---|---|---|---|
| X1L.Drug..name. | |||
| Nivolumab + Ipilimumab | 4 (44.4%) | 6 (27.3%) | 10 (32.3%) |
| Pembrolizumab | 5 (55.6%) | 16 (72.7%) | 21 (67.7%) |
| Gender | |||
| Female | 4 (44.4%) | 9 (40.9%) | 13 (41.9%) |
| Male | 5 (55.6%) | 13 (59.1%) | 18 (58.1%) |
| Age_dx | |||
| Mean (SD) | 66.8 (15.5) | 60.5 (14.3) | 62.3 (14.7) |
| Median [Min, Max] | 66.0 [47.0, 88.0] | 64.5 [38.0, 82.0] | 65.0 [38.0, 88.0] |
| YearGroup | |||
| <51yo | 2 (22.2%) | 6 (27.3%) | 8 (25.8%) |
| >50yo | 7 (77.8%) | 16 (72.7%) | 23 (74.2%) |
| Ethnicity1 | |||
| Asian | 1 (11.1%) | 6 (27.3%) | 7 (22.6%) |
| Black | 0 (0%) | 1 (4.5%) | 1 (3.2%) |
| Other | 1 (11.1%) | 0 (0%) | 1 (3.2%) |
| White | 7 (77.8%) | 15 (68.2%) | 22 (71.0%) |
| Site | |||
| Right | 5 (55.6%) | 17 (77.3%) | 22 (71.0%) |
| Left | 4 (44.4%) | 5 (22.7%) | 9 (29.0%) |
| LynchSyndrome | |||
| No | 6 (66.7%) | 15 (68.2%) | 21 (67.7%) |
| Si | 1 (11.1%) | 3 (13.6%) | 4 (12.9%) |
| Missing | 2 (22.2%) | 4 (18.2%) | 6 (19.4%) |
| T_dx | |||
| 2 | 0 (0%) | 1 (4.5%) | 1 (3.2%) |
| 3 | 3 (33.3%) | 7 (31.8%) | 10 (32.3%) |
| 4 | 6 (66.7%) | 14 (63.6%) | 20 (64.5%) |
| N_dx | |||
| 0 | 1 (11.1%) | 3 (13.6%) | 4 (12.9%) |
| 1 | 5 (55.6%) | 13 (59.1%) | 18 (58.1%) |
| 2 | 3 (33.3%) | 6 (27.3%) | 9 (29.0%) |
| M_dx | |||
| 0 | 6 (66.7%) | 8 (36.4%) | 14 (45.2%) |
| 1 | 1 (11.1%) | 14 (63.6%) | 15 (48.4%) |
| x | 2 (22.2%) | 0 (0%) | 2 (6.5%) |
| Lymph.nodes | |||
| No | 9 (100%) | 20 (90.9%) | 29 (93.5%) |
| Si | 0 (0%) | 2 (9.1%) | 2 (6.5%) |
| Lung.mets | |||
| No | 9 (100%) | 19 (86.4%) | 28 (90.3%) |
| Si | 0 (0%) | 3 (13.6%) | 3 (9.7%) |
| Liver.mets | |||
| No | 9 (100%) | 16 (72.7%) | 25 (80.6%) |
| Si | 0 (0%) | 6 (27.3%) | 6 (19.4%) |
| Bone.mets | |||
| No | 9 (100%) | 22 (100%) | 31 (100%) |
| Si | 0 (0%) | 0 (0%) | 0 (0%) |
| Differentiation | |||
| Moderate | 8 (88.9%) | 12 (54.5%) | 20 (64.5%) |
| Poor | 1 (11.1%) | 10 (45.5%) | 11 (35.5%) |
| Loss.MLH1 | |||
| No | 3 (33.3%) | 5 (22.7%) | 8 (25.8%) |
| Si | 6 (66.7%) | 17 (77.3%) | 23 (74.2%) |
| Loss.MSH2 | |||
| No | 6 (66.7%) | 18 (81.8%) | 24 (77.4%) |
| Si | 3 (33.3%) | 4 (18.2%) | 7 (22.6%) |
| Loss.MSH6 | |||
| No | 7 (77.8%) | 17 (77.3%) | 24 (77.4%) |
| Si | 2 (22.2%) | 5 (22.7%) | 7 (22.6%) |
| Loss.PMS2 | |||
| No | 3 (33.3%) | 3 (13.6%) | 6 (19.4%) |
| Si | 6 (66.7%) | 19 (86.4%) | 25 (80.6%) |
| MLH1.Promoter | |||
| No | 2 (22.2%) | 2 (9.1%) | 4 (12.9%) |
| Si | 3 (33.3%) | 3 (13.6%) | 6 (19.4%) |
| Missing | 4 (44.4%) | 17 (77.3%) | 21 (67.7%) |
| BRAFmut | |||
| No | 6 (66.7%) | 11 (50.0%) | 17 (54.8%) |
| Si | 3 (33.3%) | 10 (45.5%) | 13 (41.9%) |
| Missing | 0 (0%) | 1 (4.5%) | 1 (3.2%) |
| BRAF.mut..specify. | |||
| V600E | 3 (33.3%) | 10 (45.5%) | 13 (41.9%) |
| Missing | 6 (66.7%) | 12 (54.5%) | 18 (58.1%) |
| KRASmut | |||
| No | 6 (66.7%) | 15 (68.2%) | 21 (67.7%) |
| Si | 3 (33.3%) | 6 (27.3%) | 9 (29.0%) |
| Missing | 0 (0%) | 1 (4.5%) | 1 (3.2%) |
| KRAS.mut..specify. | |||
| A146W | 0 (0%) | 1 (4.5%) | 1 (3.2%) |
| G12D | 1 (11.1%) | 1 (4.5%) | 2 (6.5%) |
| G12D, A146W | 1 (11.1%) | 0 (0%) | 1 (3.2%) |
| G12D, G12R | 0 (0%) | 2 (9.1%) | 2 (6.5%) |
| G12W | 1 (11.1%) | 0 (0%) | 1 (3.2%) |
| G13D | 0 (0%) | 2 (9.1%) | 2 (6.5%) |
| Missing | 6 (66.7%) | 16 (72.7%) | 22 (71.0%) |
| PIK3CAmut | |||
| No | 6 (66.7%) | 12 (54.5%) | 18 (58.1%) |
| Si | 3 (33.3%) | 9 (40.9%) | 12 (38.7%) |
| Missing | 0 (0%) | 1 (4.5%) | 1 (3.2%) |
| TP53mut | |||
| No | 5 (55.6%) | 18 (81.8%) | 23 (74.2%) |
| Si | 4 (44.4%) | 3 (13.6%) | 7 (22.6%) |
| Missing | 0 (0%) | 1 (4.5%) | 1 (3.2%) |
| CEA.dx.positive | |||
| No | 2 (22.2%) | 9 (40.9%) | 11 (35.5%) |
| Si | 4 (44.4%) | 10 (45.5%) | 14 (45.2%) |
| Missing | 3 (33.3%) | 3 (13.6%) | 6 (19.4%) |
| CA19.9.dx.positive | |||
| No | 2 (22.2%) | 5 (22.7%) | 7 (22.6%) |
| Si | 2 (22.2%) | 2 (9.1%) | 4 (12.9%) |
| Missing | 5 (55.6%) | 15 (68.2%) | 20 (64.5%) |
| Surgery | |||
| No | 3 (33.3%) | 8 (36.4%) | 11 (35.5%) |
| Si | 6 (66.7%) | 14 (63.6%) | 20 (64.5%) |
| PO.Therapy | |||
| No | 8 (88.9%) | 17 (77.3%) | 25 (80.6%) |
| NeoA | 1 (11.1%) | 3 (13.6%) | 4 (12.9%) |
| Adj | 0 (0%) | 2 (9.1%) | 2 (6.5%) |
| Type.Surgery | |||
| None | 5 (55.6%) | 8 (36.4%) | 13 (41.9%) |
| Elective | 3 (33.3%) | 9 (40.9%) | 12 (38.7%) |
| Emergency | 0 (0%) | 4 (18.2%) | 4 (12.9%) |
| Symptom control | 1 (11.1%) | 1 (4.5%) | 2 (6.5%) |
| IO.Prior.Surgery | |||
| No | 4 (44.4%) | 21 (95.5%) | 25 (80.6%) |
| Si | 5 (55.6%) | 1 (4.5%) | 6 (19.4%) |
| number.ipilimumab | |||
| 1 | 3 (33.3%) | 1 (4.5%) | 4 (12.9%) |
| 4 | 1 (11.1%) | 5 (22.7%) | 6 (19.4%) |
| Missing | 5 (55.6%) | 16 (72.7%) | 21 (67.7%) |
| X1L.NLR.at.week.0 | |||
| Mean (SD) | 4.14 (2.14) | 4.00 (3.25) | 4.04 (2.93) |
| Median [Min, Max] | 4.15 [0.890, 8.85] | 2.93 [1.31, 15.7] | 3.33 [0.890, 15.7] |
| NLR.week0 | |||
| ≥3 | 7 (77.8%) | 10 (45.5%) | 17 (54.8%) |
| <3 | 2 (22.2%) | 12 (54.5%) | 14 (45.2%) |
| X1L.NLR.at.week.12 | |||
| Mean (SD) | 2.39 (0.957) | 3.19 (3.33) | 2.94 (2.82) |
| Median [Min, Max] | 2.31 [1.17, 3.95] | 2.19 [1.08, 15.1] | 2.19 [1.08, 15.1] |
| Missing | 0 (0%) | 2 (9.1%) | 2 (6.5%) |
| NLR.week12 | |||
| ≥3 | 2 (22.2%) | 6 (27.3%) | 8 (25.8%) |
| <3 | 7 (77.8%) | 14 (63.6%) | 21 (67.7%) |
| Missing | 0 (0%) | 2 (9.1%) | 2 (6.5%) |
| CEA_week0 | |||
| Mean (SD) | 18.7 (25.6) | 133 (527) | 102 (449) |
| Median [Min, Max] | 6.50 [1.50, 67.2] | 9.40 [1.10, 2430] | 7.00 [1.10, 2430] |
| Missing | 1 (11.1%) | 1 (4.5%) | 2 (6.5%) |
| CEA_week12 | |||
| Mean (SD) | 14.6 (20.6) | 48.4 (175) | 38.9 (148) |
| Median [Min, Max] | 2.90 [1.00, 53.6] | 3.35 [1.30, 747] | 3.20 [1.00, 747] |
| Missing | 2 (22.2%) | 4 (18.2%) | 6 (19.4%) |
| Response | |||
| CR | 2 (22.2%) | 1 (4.5%) | 3 (9.7%) |
| PR | 2 (22.2%) | 10 (45.5%) | 12 (38.7%) |
| SD | 4 (44.4%) | 4 (18.2%) | 8 (25.8%) |
| PD | 0 (0%) | 5 (22.7%) | 5 (16.1%) |
| Missing | 1 (11.1%) | 2 (9.1%) | 3 (9.7%) |
| PFSm | |||
| Mean (SD) | 9.59 (6.28) | 13.2 (13.8) | 12.1 (12.1) |
| Median [Min, Max] | 7.16 [3.55, 20.5] | 8.77 [-2.76, 53.7] | 8.61 [-2.76, 53.7] |
| OSm | |||
| Mean (SD) | 9.59 (6.28) | 16.0 (13.9) | 14.2 (12.4) |
| Median [Min, Max] | 7.16 [3.55, 20.5] | 11.3 [0.821, 53.7] | 10.8 [0.821, 53.7] |
| x1L.Tox.G3.4 | |||
| No | 5 (55.6%) | 11 (50.0%) | 16 (51.6%) |
| Si | 4 (44.4%) | 8 (36.4%) | 12 (38.7%) |
| Missing | 0 (0%) | 3 (13.6%) | 3 (9.7%) |
| x1L.IO.Tox.PDN | |||
| No | 7 (77.8%) | 20 (90.9%) | 27 (87.1%) |
| Si | 2 (22.2%) | 2 (9.1%) | 4 (12.9%) |
Analysis by Death
| No | Si | p | test | |
|---|---|---|---|---|
| n | 26 | 5 | ||
| Setting.Prior.IO = Metastatic (%) | 17 (65.4) | 5 (100.0) | 0.306 | |
| X1L.Drug..name. = Pembrolizumab (%) | 16 (61.5) | 5 (100.0) | 0.245 | |
| YearGroup = >50yo (%) | 19 (73.1) | 4 ( 80.0) | 1.000 | |
| Ethnicity2 = White (%) | 17 (65.4) | 5 (100.0) | 0.306 | |
| Site = Left (%) | 8 (30.8) | 1 ( 20.0) | 1.000 | |
| Differentiation = Poor (%) | 7 (26.9) | 4 ( 80.0) | 0.078 | |
| Loss.MLH1 = Si (%) | 18 (69.2) | 5 (100.0) | 0.378 | |
| Loss.PMS2 = Si (%) | 20 (76.9) | 5 (100.0) | 0.563 | |
| PIK3CAmut = Si (%) | 11 (44.0) | 1 ( 20.0) | 0.617 | |
| TP53mut = Si (%) | 5 (20.0) | 2 ( 40.0) | 0.699 | |
| KRASmut = Si (%) | 9 (36.0) | 0 ( 0.0) | 0.285 | |
| BRAFmut = Si (%) | 8 (32.0) | 5 (100.0) | 0.021 | |
| LynchSyndrome = Si (%) | 4 (20.0) | 0 ( 0.0) | 0.682 | |
| Lung.mets = Si (%) | 0 ( 0.0) | 3 ( 60.0) | 0.001 | |
| Liver.mets = Si (%) | 3 (11.5) | 3 ( 60.0) | 0.058 | |
| Surgery = Si (%) | 19 (73.1) | 1 ( 20.0) | 0.078 | |
| CEA.dx.positive = Si (%) | 12 (60.0) | 2 ( 40.0) | 0.763 | |
| NLR.week0 = <3 (%) | 13 (50.0) | 1 ( 20.0) | 0.457 | |
| NLR.week12 = <3 (%) | 20 (76.9) | 1 ( 33.3) | 0.359 | |
| ORR = ORR (%) | 15 (60.0) | 0 ( 0.0) | 0.175 | |
| x1L.Tox.G3.4 = Si (%) | 9 (37.5) | 3 ( 75.0) | 0.391 | |
| x1L.IO.Tox.PDN = Si (%) | 3 (11.5) | 1 ( 20.0) | 1.000 |
MMR IHC and BRAF mut analysis
Median follow-up times
Median follow-up overall
## Quantiles of the potential follow up time distribution based on the Kaplan-Meier method
## applied to the censored times reversing the roles of event status and censored.
##
## Table of quantiles and corresponding confidence limits:
## q quantile lower upper
## <num> <num> <num> <num>
## 1: 0.00 NA NA NA
## 2: 0.25 25.4 12.5 35.9
## 3: 0.50 12.2 8.6 17.9
## 4: 0.75 7.6 4.5 10.8
## 5: 1.00 3.5 3.5 4.5
##
##
## Median with interquartile range (IQR):
## Median (IQR)
## <char>
## 1: 12.22 (7.62;25.36)## Quantiles of the potential follow up time distribution based on the Kaplan-Meier method
## applied to the censored times reversing the roles of event status and censored.
##
## Table of quantiles and corresponding confidence limits:
## q quantile lower upper
## <num> <num> <num> <num>
## 1: 0.00 NA NA NA
## 2: 0.25 8.0 6.1 NA
## 3: 0.50 7.2 3.9 8.0
## 4: 0.75 3.9 3.5 7.2
## 5: 1.00 3.5 3.5 3.9
##
##
## Median with interquartile range (IQR):
## Median (IQR)
## <char>
## 1: 7.16 (3.94;7.95)## Quantiles of the potential follow up time distribution based on the Kaplan-Meier method
## applied to the censored times reversing the roles of event status and censored.
##
## Table of quantiles and corresponding confidence limits:
## q quantile lower upper
## <num> <num> <num> <num>
## 1: 0.00 NA NA NA
## 2: 0.25 33.0 17.9 38
## 3: 0.50 17.9 12.5 28
## 4: 0.75 12.2 9.4 18
## 5: 1.00 4.5 4.5 11
##
##
## Median with interquartile range (IQR):
## Median (IQR)
## <char>
## 1: 17.87 (12.22;33.02)Progression Free Survival
Overall population
By Drug
By Setting
By BRAF status
By ADC differentiation
By NLR at week 12
Overall Survival in all population
Overall population
By Drug
By Setting
By BRAF status
By Lynch Syndrome
By ADC differentiation
By NLR at week 0
By NLR at week 12
Overall Survival in M1
Overall population
By Drug
By BRAF status
By Lynch Syndrome
By ADC differentiation
By NLR at week 0
By NLR at week 12
